Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial

Affiliations

¹ Probity Medical Research, Waterloo, Ontario, Canada.
² Dermatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
³ Department of Medicine (Dermatology) and Department of Dermatology, The University of Melbourne, St Vincent's Hospital Melbourne, Melbourne, Victoria and Skin and Cancer Foundation, Carlton, Victoria, Australia.
⁴ Pharmacokinetics and Drug Metabolism, Amgen, Seattle, Washington, USA.
⁵ Early Development, Amgen, Thousand Oaks, California, USA.
⁶ Biostatistics, Amgen, South San Francisco, California, USA.
⁷ Rockefeller University, New York, New York, USA.
⁸ Medical Sciences, Amgen, Seattle, Washington, USA.
⁹ Medical Sciences, Amgen, Seattle, Washington, USA. Electronic address: davidm02@amgen.com.

Free article

Clinical Trial

Kim A Papp et al. J Invest Dermatol. 2012 Oct.

Free article

. 2012 Oct;132(10):2466-2469.

doi: 10.1038/jid.2012.163. Epub 2012 May 24.

¹ Probity Medical Research, Waterloo, Ontario, Canada.
² Dermatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
³ Department of Medicine (Dermatology) and Department of Dermatology, The University of Melbourne, St Vincent's Hospital Melbourne, Melbourne, Victoria and Skin and Cancer Foundation, Carlton, Victoria, Australia.
⁴ Pharmacokinetics and Drug Metabolism, Amgen, Seattle, Washington, USA.
⁵ Early Development, Amgen, Thousand Oaks, California, USA.
⁶ Biostatistics, Amgen, South San Francisco, California, USA.
⁷ Rockefeller University, New York, New York, USA.
⁸ Medical Sciences, Amgen, Seattle, Washington, USA.
⁹ Medical Sciences, Amgen, Seattle, Washington, USA. Electronic address: davidm02@amgen.com.

No abstract available

Publication types